Search

Your search keyword '"Ezetimibe therapeutic use"' showing total 3 results
Start Over Descriptor "Ezetimibe therapeutic use" Language french
3 results on '"Ezetimibe therapeutic use"'

1. [First-line treatment of hypercholesterolemia : start with statin monotherapy or ezetimibe-statin combination ?]

Author

Scheen A, Wallemacq C, and Lancellotti P

Subjects
Humans, Cholesterol, Cholesterol, LDL, Drug Therapy, Combination, Ezetimibe therapeutic use, Treatment Outcome, Anticholesteremic Agents therapeutic use, Azetidines therapeutic use, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Hypercholesterolemia drug therapy
Abstract

Hypercholesterolemia, especially LDL-C («Low-Density-Lipoprotein - Cholesterol»), is a major cardiovascular risk factor, especially for coronary artery disease. Patients at high or very high cardiovascular risk should reach LDL concentrations as low as possible («the lower, the better»), with a reduction of at least 50 % from baseline levels according to the most recent guidelines, especially those in secondary prevention. An ezetimibe-statin combination most often allows to reach this goal thanks to a complementary action. The objectives of this article are to remind the dual actions of these two medications, to summarize the clinical evidence showing not only a remarkable cholesterol-lowering effect but also a reduction in cardiovascular events in both controlled trials and observational real-life studies, to specify the positioning of this combined oral therapy in the last international guidelines and to mention pharmaceutical specialties that combine ezetimibe with a statin available for the practitioner.

Published
2024

2. [FIXED COMBINATION ATORVASTATIN-EZETIMIBE (ATOZET®)].

Author

Scheen AJ

Subjects
Anticholesteremic Agents administration & dosage, Anticholesteremic Agents therapeutic use, Atorvastatin therapeutic use, Cardiovascular Diseases etiology, Drug Combinations, Ezetimibe therapeutic use, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use, Hypercholesterolemia complications, Hypercholesterolemia drug therapy, Risk Factors, Atorvastatin administration & dosage, Cardiovascular Diseases prevention & control, Ezetimibe administration & dosage
Abstract

Cardiovascular prevention in subjects at high or very high risk requires a drastic reduction in LDL cholesterol according to the concept "the lower, the better". The combination of an inhibitor of cholesterol synthesis and a selective inhibitor of intestinal absorption results in a complementary and synergistic LDL-lowering activity. Besides a first fixed combination ezetimibe-simvastatin (Inegy®), a new fixed combination is presented, Atozet® that combines atorvastatin and ezetimibe. Because atorvastatin is more potent than simvastatin, this novel fixed combination should facilitate reaching therapeutic goals in terms of LDL cholesterol amongst patients with severe hypercholesterolaemia and/or at high or very high cardiovascular risk.

Published
2016

3. [ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].

Author

Lancellotti P, Pierard LA, and Scheen AJ

Subjects
Anticholesteremic Agents administration & dosage, Anticholesteremic Agents adverse effects, Cardiovascular Diseases epidemiology, Cholesterol, LDL drug effects, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Ezetimibe administration & dosage, Ezetimibe adverse effects, Ezetimibe therapeutic use, Female, Follow-Up Studies, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors administration & dosage, Hydroxymethylglutaryl-CoA Reductase Inhibitors adverse effects, Male, Middle Aged, Prognosis, Simvastatin administration & dosage, Simvastatin adverse effects, Simvastatin therapeutic use, Treatment Outcome, Acute Coronary Syndrome drug therapy, Anticholesteremic Agents therapeutic use, Cardiovascular Diseases prevention & control, Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use
Abstract

Statins reduce both LDL cholesterol (LDL-C) levels and the risk of cardiovascular events in patients with and without cardiovascular disease. Intensive statin therapy, compared with moderate-dose statin therapy, incrementally lowers LDL-C levels and rates of cardiovascular events in patients presenting with acute coronary syndrome. Ezetimibe, by diminishing the absorption of cholesterol from the intestine, additionally reduces LDL-C when added to statins. In this article, we discuss the potential benefits of the combination of simvastatin and ezetimibe for the long-term management of patients with acute coronary syndrome through an analysis of the IMPROVE-IT results (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial). This randomised double blind trial included 18,144 patients with a LDL-C of 50 to 100 (with statin) or 125 (without statin) mg/dl and had a median follow-up of 6 years. The objective of the study was to test the efficacy of simvastatin 40 mg versus simvastatin 40 mg and 10 mg ezetimibe. The primary endpoint included cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina and coronary revascularization. The addition of ezetimibe to simvastatin resulted in an incremental lowering of LDL-C (reached value 53.2 versus 69.9 mg/dl, p < 0.001) and a further improvement of the patient prognosis (relative reduction of primary endpoint: -6.4%, p = 0.016). In addition, the combined therapy showed no significant adverse effects, particularly regarding the risk of cancers, which confirms the safety of ezetimibe. In acute coronary syndrome, the prescription of ezetimibe should be considered (class HA, level of evidence B) in patients with a LDL-C a 70 mg/dl despite maximally tolerated dose of statin.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results